Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B.
Joyce, M.G., Bao, A., Chen, M., Georgiev, I.S., Ou, L., Bylund, T., Druz, A., Kong, W.P., Peng, D., Rundlet, E.J., Van Galen, J.G., Wang, S., Yang, Y., Zhang, B., Chuang, G.Y., McLellan, J.S., Graham, B.S., Mascola, J.R., Kwong, P.D.(2019) Pathog Immun 4: 294-323
- PubMed: 31893251 
- DOI: https://doi.org/10.20411/pai.v4i2.338
- Primary Citation of Related Structures:  
6Q0S - PubMed Abstract: 
Respiratory syncytial virus (RSV) subtypes, A and B, co-circulate in annual epidemics and alternate in dominance. We have shown that a subtype A RSV fusion (F) glycoprotein, stabilized in its prefusion conformation by DS-Cav1 mutations, is a promising RSV-vaccine immunogen, capable of boosting RSV-neutralizing titers in healthy adults. In both humans and vaccine-tested animals, neutralizing titers elicited by this subtype A DS-Cav1 immunogen were ~ 2- to 3-fold higher against the homologous subtype A virus than against the heterologous subtype B virus.
Organizational Affiliation: 
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.